NewAmsterdam Pharma Company N.V. (NAMS)
| Market Cap | 2.36B |
| Revenue (ttm) | 33.59M |
| Net Income (ttm) | -198.92M |
| Shares Out | 92.39M |
| EPS (ttm) | -2.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,004,960 |
| Open | 24.86 |
| Previous Close | 25.46 |
| Day's Range | 24.55 - 26.25 |
| 52-Week Range | 10.50 - 27.29 |
| Beta | 0.07 |
| Analysts | Strong Buy |
| Price Target | 36.20 (+41.96%) |
| Earnings Date | Feb 6, 2025 |
About NAMS
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in N... [Read more]
Financial Performance
In 2023, NAMS's revenue was $14.09 million, a decrease of -86.28% compared to the previous year's $102.69 million. Losses were -$176.94 million, 681.7% more than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NAMS stock is "Strong Buy." The 12-month stock price forecast is $36.2, which is an increase of 41.96% from the latest price.
News
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
NAARDEN, The Netherlands and MIAMI, Dec. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company...
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
NAARDEN, the Netherlands and MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company...
NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts
NewAmsterdam Pharma Company N.V.'s drug obicetrapib achieved positive results in phase 3 BROADWAY study, significantly reducing LDL-C in ASCVD and HeFH patients when added to statins. Positive data en...
Top 3 Health Care Stocks That May Collapse This Quarter
As of Dec. 11, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
NAARDEN, The Netherlands and MIAMI, Dec. 10, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company...
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?
On Tuesday, NewAmsterdam Pharma Company N.V. NAMS revealed topline data from its Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with atherosclerotic cardiovascular disease (...
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia
-- Achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Dec. 06, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 – – Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% at day 365 – – Total LDL-P ...
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
NAARDEN, The Netherlands and MIAMI, Oct. 28, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...
Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies
NewAmsterdam Pharma's Obicetrapib, a CETP inhibitor, shows promise in reducing LDL-C, addressing unmet cardiovascular needs, and has favorable Phase 3 trial results. Obicetrapib's potential regulatory...
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
NAARDEN, The Netherlands and MIAMI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...
NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside
Needham has initiated coverage on NewAmsterdam Pharma Company N.V NAMS, a clinical-stage biopharma developing obicetrapib, an orally-dosed CETP inhibitor for lowering cholesterol.
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
-- Company expects to report topline data in the first quarter of 2025 -- -- Company expects to report topline data in the first quarter of 2025 --
NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year Period
NewAmsterdam Pharma Company N.V. expects data from the BROOKLYN study, using obicetrapib for the treatment of patients with HeFH, in Q3 of 2024. Data from the BROADWAY study, using obicetrapib for the...
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
-- Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT-- -- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 --
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
Enrollment to continue to the end of April to accommodate strong patient and site interest Enrollment to continue to the end of April to accommodate strong patient and site interest
BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors
RICHMOND, Calif.--(BUSINESS WIRE)-- #aging--BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biolog...
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
NAARDEN, the Netherlands and MIAMI, April 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical comp...
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
NAARDEN, the Netherlands and MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical comp...
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
-- TANDEM is designed to evaluate obicetrapib and ezetimibe fixed-dose combination (“FDC”) as an adjunct to diet and maximally tolerated lipid lowering therapy in patients with HeFH, ASCVD or ASCVD ri...
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
-- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 -- -- Plan to initiate TANDEM, pivotal Phase 3 trial evaluating obicetr...
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
NAARDEN, the Netherlands and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company...
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
NAARDEN, The Netherlands and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company...